Enasidenib is primarily used in the treatment of relapsed or refractory acute myeloid leukemia (AML) with a specific genetic mutation. It targets the IDH2 enzyme, which is often mutated in certain cancers, including AML. By inhibiting this mutated enzyme, enasidenib helps to restore normal cell differentiation, reducing the growth of cancerous cells. It is particularly beneficial for patients who have not responded well to other treatments, offering a targeted therapy option. The drug is administered orally, making it convenient for long-term use. Clinical studies have shown that enasidenib can improve overall survival and reduce the need for blood transfusions in some patients. It represents a significant advancement in personalized medicine for AML patients with IDH2 mutations.